What the Guidelines Actually Cover
The MHLW guidelines are not a single PDF—they are a series of notifications and standards. The key document is "Guidelines for Clinical Research Using Human Stem Cells" (2010, revised 2019), which mandates that any stem cell therapy must be overseen by a certified Institutional Review Board (IRB) and registered with the Japan Registry of Clinical Trials (jRCT). For medical care (as opposed to research), the ASRM requires clinics to submit a "Planned Provision of Regenerative Medicine" to the MHLW, which is then reviewed by a specialized committee. As of 2023, over 4,500 such plans have been filed, but only about 1,200 have been approved for active use—the rest are still under review or rejected due to insufficient safety data.
Here is a breakdown of the approval tiers under the ASRM:
| Risk Class | Examples | Review Body | Approval Time (Average) |
|---|---|---|---|
| Class I (High risk) | iPS cells, embryonic stem cells | MHLW Special Committee | 12–18 months |
| Class II (Medium risk) | Autologous mesenchymal stem cells, cultured cells | Certified IRB | 6–12 months |
| Class III (Low risk) | Uncultured, minimally manipulated cells (e.g., adipose-derived stromal vascular fraction) | Clinic's own ethics committee | 3–6 months |
Class III is where most "stem cell tourism" clinics operate, but the guidelines are strict: even for Class III, the clinic must submit a standard operating procedure (SOP) for cell processing, storage, and transport. The MHLW inspects these facilities randomly—in 2022, 14% of Class III clinics were flagged for non-compliance, mainly for poor record-keeping or lack of sterile processing validation.
Cell Processing and Quality Control
The guidelines mandate that all stem cell products must be manufactured in a Cell Processing Facility (CPF) that meets Good Manufacturing Practice (GMP) standards. This is not optional. The CPF must be registered with the MHLW, and each batch of cells must pass sterility tests (including endotoxin and mycoplasma screening), viability assays (minimum 70% viability for intravenous use), and potency tests (e.g., differentiation capacity for mesenchymal stem cells). Data from the Japanese Society for Regenerative Medicine shows that in 2023, 8.3% of batches failed initial sterility checks—these were discarded, and the clinics were required to report the failure to the MHLW within 48 hours.
For autologous treatments (using the patient's own cells), the guidelines require a minimum of two separate blood tests for infectious diseases (HIV, HBV, HCV, HTLV-1, syphilis) before cell collection. The second test must be done within 14 days of the collection date. If the patient has a positive result for any of these, the cells cannot be used unless the treatment is for a life-threatening condition and the patient gives explicit informed consent. This is a direct response to the 2018 scandal where a clinic in Tokyo used contaminated cells from a patient with undiagnosed hepatitis B, leading to a temporary suspension of all Class III treatments in that prefecture.
Informed Consent and Patient Documentation
The guidelines are obsessive about consent forms. They must include: the specific type of stem cell (e.g., "bone marrow-derived mesenchymal stem cells" not just "stem cells"), the number of cells to be administered, the route of administration, the expected mechanism of action (with citations), a list of all potential side effects (including unknown risks), and the cost breakdown. The MHLW requires that the consent form be signed at least 7 days before the procedure, and the patient must be given a copy of the form that includes the contact information of the clinic's IRB. In 2021, a survey of 200 clinics found that 22% were not providing the full 7-day waiting period—the MHLW fined those clinics and published their names on the official website.
Here is the minimum data that must be in the consent form, according to the guidelines:
- Cell source (autologous vs. allogeneic, tissue type)
- Processing method (e.g., culture with fetal bovine serum vs. human platelet lysate)
- Number of treatment sessions and interval between sessions
- Follow-up schedule (minimum 6 months for Class III, 2 years for Class I)
- Reporting of adverse events (within 24 hours for serious events)
- Right to withdraw from the treatment at any time
Treatment Process: From Consultation to Follow-Up
The guidelines lay out a specific sequence. First, the patient must have a documented diagnosis from a licensed physician in Japan. The clinic then confirms that the patient meets the inclusion criteria (e.g., for osteoarthritis, the patient must have Kellgren-Lawrence grade 2 or higher on X-ray). Then, the clinic submits the treatment plan to the IRB or MHLW committee, depending on the risk class. After approval, the cell collection is scheduled. For adipose-derived stem cells, the liposuction procedure must be performed in a licensed operating room, and the harvested tissue must be sent to the CPF within 4 hours. The cells are then processed, typically taking 2–4 weeks for culture expansion. The final product is released only after the quality control tests are passed. The administration is done in a clinic setting, and the patient is monitored for at least 2 hours post-injection for immediate allergic reactions. Follow-up visits are required at 1, 3, 6, and 12 months, with blood tests and imaging (MRI or ultrasound) to track efficacy and safety.
Data from the MHLW's 2023 annual report shows that the most common adverse events are injection site pain (12% of patients), fever (4%), and transient swelling (3%). Serious adverse events (e.g., infection, tumor formation) were reported in 0.2% of cases, all of which were in Class II treatments involving repeated injections of allogeneic cells. The guidelines require that any serious adverse event be reported to the MHLW within 7 days, and the treatment protocol must be put on hold until the investigation is complete.
Cost and Insurance Coverage
Stem cell treatments in Japan are not covered by public health insurance, except for a few approved procedures like hematopoietic stem cell transplantation for leukemia. The guidelines do not set prices, but they require clinics to disclose the full cost upfront. A typical Class III treatment (e.g., for knee osteoarthritis) costs between ¥1,500,000 and ¥3,000,000 (approximately $10,000–$20,000 USD) for a single injection. Class II treatments (e.g., for spinal cord injury) can range from ¥5,000,000 to ¥10,000,000. The MHLW has warned that clinics charging significantly below these averages are likely cutting corners on cell processing or quality control. In 2022, the MHLW shut down a clinic in Osaka that was charging ¥500,000 for "stem cell injections" that were later found to be saline with no viable cells.
Where to Find the Official Documents
The MHLW publishes all approved treatment plans and guidelines on the "Regenerative Medicine Information Portal" (https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/iryou/regenerative_medicine.html). The documents are in Japanese, but the English summaries are available for some sections. The Japanese Society for Regenerative Medicine also publishes clinical practice guidelines for specific conditions (e.g., "Guidelines for the Use of Mesenchymal Stem Cells in Osteoarthritis", 2021 edition). These guidelines are updated every 3–5 years, and the latest revision for stem cell processing was released in March 2023. If you want to see how these guidelines are applied in real clinics, you can read Japan Medical on stem cell treatment process in Japan, which includes case studies and compliance checklists.
Enforcement and Penalties
The guidelines are not optional. The ASRM gives the MHLW the power to suspend or revoke a clinic's license for non-compliance. In 2023, 17 clinics had their licenses suspended for violations such as using unapproved cell sources (e.g., fetal stem cells imported from overseas), failing to report adverse events, or not having a registered CPF. The MHLW also publishes a "blacklist" of clinics that have been fined or shut down, which is updated quarterly. The penalties include fines of up to ¥10,000,000 and criminal charges for repeated violations. The guidelines also require that all clinic staff, including the physicians and cell processing technicians, complete a certified training program on regenerative medicine ethics and safety. As of 2024, over 3,000 healthcare professionals have completed this training.
Key Differences from Other Countries
Japan's guidelines are more stringent than the US FDA's "enforcement discretion" approach for autologous cells, but less rigid than the EU's ATMP (Advanced Therapy Medicinal Products) regulations. For example, Japan allows Class III treatments to proceed with only an ethics committee review, while the EU requires a national competent authority approval for all cell-based therapies. However, Japan's follow-up requirements are stricter: the US does not mandate a minimum 2-year follow-up for Class I treatments, but Japan does. This has led to a higher data collection rate—Japan's registry has over 15,000 patient records, compared to fewer than 5,000 in the US for similar treatments.
Another difference is the handling of allogeneic cells. Japan's guidelines require that allogeneic donors be screened for a broader panel of infectious diseases (including HTLV-1, which is rare in the West but prevalent in Japan), and the donor must be re-tested every 6 months if the cells are stored for future use. The MHLW also bans the use of embryonic stem cells from sources other than the approved lines (e.g., the Kyoto University iPS cell bank), and all research using iPS cells must be registered with the MHLW's iPS Cell Research Committee.
Practical Tips for Patients
If you are considering a stem cell treatment in Japan, the first step is to check if the clinic is registered on the MHLW's official list of approved providers. This list is public and includes the clinic's risk class, the specific cell type they are authorized to use, and the expiry date of their approval. You should also ask for the batch release certificate for the cells you will receive—this document shows the sterility test results, viability, and potency data. If the clinic cannot provide this, do not proceed. The guidelines also require that the clinic give you a "patient information leaflet" that explains the treatment in plain language—this is separate from the consent form. If the leaflet uses vague terms like "stem cell therapy" without specifying the cell type or source, that is a red flag.
Finally, the guidelines allow you to request a second opinion from another registered clinic or from the MHLW's consultation service. The MHLW has a hotline (03-5253-1111) for patient inquiries, and they can confirm whether a specific treatment plan has been approved. This is a free service, and it is available in English on weekdays. The MHLW also publishes a monthly newsletter on regenerative medicine safety, which includes updates on new guidelines and reported adverse events. You can subscribe to this newsletter on the MHLW website.